Search Here

Unmet medical needs present a profound challenge, yet the drug development process often stumbles under its own weight. The complexities and lengthy processes in traditional pharma innovation lead to high costs and therapies that frequently fail to meet patients' needs. This is especially evident in the treatment of complex, obesity-related, and cardiovascular diseases, where existing solutions often only scratch the surface of these multifaceted conditions.

The iMetabolic Biopharma Corporation (iMBP) is tackling the challenge head-on with its proprietary iPlatform^TM, which is a cutting-edge fusion of biotechnology and artificial intelligence (AI). "Our solution is techbio (technology-enhanced biopharma), which has led to the establishment of a proprietary multi-drug candidate pipeline and AI drug discovery technology," explains Founder and CEO Dr. Urban A. Kiernan.

By integrating AI into key steps of drug discovery, from dynamic modeling of therapeutic targets to streamlining testing and development, iMBP transforms the laborious and inefficient process into a nimble, precision-driven operation. This not only accelerates the discovery of new, more effective treatments but also enables continual innovation down the road. Best of all, it promises to make these therapies more affordable and accessible. "Our prime directive is to develop therapeutics for the treatment of diseases with high unmet medical needs," asserts Kiernan.

Currently, iMBP's focus is concentrated on three critical disease areas: cardiometabolic, cardiovascular, and neurodegenerative diseases. These conditions, including fat metabolism, atherosclerotic cardiovascular disease, and Alzheimer's disease, not only have a significant impact on public health but also present substantial challenges for current treatment methodologies.

For example, cardiovascular disease, Kiernan explains, remains the leading cause of death in the United States despite advances in cholesterol-lowering treatments. iMBP's innovative approach aims to address the underlying causes of these diseases rather than just their symptoms.

Kiernan adds, "Despite numerous treatments and dietary interventions, the prevalence of these diseases remains stubbornly high. One reason for this is the limitations of current treatments. Our focus is on improving the return process of lipoproteins to the liver, aiming to address the root causes of atherosclerosis. Our strategy could significantly change how we treat cardiovascular conditions and offer new hope to patients and healthcare providers alike."

The iMBP 'Incubator'

iMetabolic Biopharma operates with an incubator-like mindset, constantly evolving and refining its methodologies to address emerging challenges in drug development. Kiernan, a former Director of Biomarker Discovery at Intrinsic Bioprobes, Inc., and Global Business Development Manager at Thermo Fisher Scientific, emphasizes the importance of a fresh perspective: "You don't have to be Einstein to go and figure things out, but you do need to be able to approach a problem from different angles and that is exactly how I approach a disease. Being a doctor, that is where my value comes in. It's taking a different look at the problem and then developing a different solution."

iMBP's Vast Potential

iMBP's achievements extend beyond its internal innovations. The company has forged significant partnerships with industry leaders such as OmniAb, Amazon Web Services (AWS), and Nvidia. These collaborations, along with an NIH SBIR Award, highlight iMBP's commitment and showcase their success in advancing biopharma through advanced technology and strategic alliances.

iMetabolic Biopharma Corporation embodies a new era of drug development, defined by its innovative use of AI and proprietary technologies. With a clear mission to address high unmet medical needs and a dedication to improving patient care, iMBP is set to make a lasting impact on the biopharma industry. By focusing on diseases with significant gaps in current treatment options and leveraging advanced technologies, iMBP is not just making drugs—it's reshaping the future of medicine.

Join forces with iMBP today and be a part of creating a world where people live longer, healthier, and happier lives.